Skip to main content
Home > Week in Review > Clinical Status

Chronological Index of : Clinical Status

 Current Issue
  • Abatacept: Clinical trial started

    Simcere Pharmaceutical Group, Nanjing, China Ono Pharmaceutical Co. Ltd. (Tokyo:4528), Osaka, Japan Bristol-Myers Squibb Co. (NYSE:BMY), New York, N.Y. Product: Abatacept (subcutaneous) (ONO-4164 SC, BMS-188667SC) …

    Published on 4/13/2015
  • Aerucin: Phase I started

    Aridis Pharmaceuticals Inc., San Jose, Calif. Product: Aerucin Business: Infectious Molecular target: NA Description: Human IgG1 mAb against Pseudomonas aeruginosa Indication: Adjunct treatment of acute pneumonia …

    Published on 4/13/2015
  • BTT-1023: Phase IIa started

    Biotie Therapies Corp. (HSE:BTH1V), Turku, Finland Product: BTT-1023, BTT1023 Business: Hepatic Molecular target: Vascular adhesion protein-1 (VAP-1) (SSAO) Description: Human mAb against vascular adhesion protein-1 (…

    Published on 4/13/2015
  • C-Cure: Phase III ongoing

    Cardio3 BioSciences S.A. (Euronext:CARD), Mont-Saint-Guibert, Belgium Product: C-Cure, C3BS-CQR-1 Business: Cardiovascular Molecular target: NA Description: Cellular therapy based on autologous stem cells differentiated…

    Published on 4/13/2015
  • Cenderitide: Completed Phase II enrollment

    Capricor Therapeutics Inc. (NASDAQ:CAPR), Beverly Hills, Calif. Product: Cenderitide (formerly CD-NP) Business: Cardiovascular Molecular target: Natriuretic peptide receptor A (NPR1) (NPRA); Natriuretic peptide receptor…

    Published on 4/13/2015
  • EndoBarrier: Pivotal trial hold

    GI Dynamics Inc. (ASX:GID), Lexington, Mass. Product: EndoBarrier, EndoBarrier Gastrointestinal Liner Business: Endocrine/Metabolic Molecular target: NA Description: Non-surgical liner endoscopically placed in the GI …

    Published on 4/13/2015
  • Imbruvica ibrutinib: Phase Ib/II started

    Pharmacyclics Inc. (NASDAQ:PCYC), Sunnyvale, Calif. Johnson & Johnson (NYSE:JNJ), New Brunswick, N.J. Product: Imbruvica ibrutinib (PCI-32765) Business: Cancer Molecular target: Brutons tyrosine kinase (Btk) Description…

    Published on 4/13/2015
  • Lirilumab: Phase II amended

    Innate Pharma S.A. (Euronext:IPH), Marseille, France Ono Pharmaceutical Co. Ltd. (Tokyo:4528), Osaka, Japan Bristol-Myers Squibb Co. (NYSE:BMY), New York, N.Y. Product: Lirilumab (BMS-986015, IPH2102) Business: Cancer …

    Published on 4/13/2015
  • MEDI4736: Phase Ib/II started

    AstraZeneca plc (LSE:AZN; NYSE:AZN), London, U.K. Product: MEDI4736 Business: Cancer Molecular target: Programmed cell death 1 ligand 1 (PD-L1) (B7-H1) (CD274) Description: Human IgG1 mAb targeting programmed cell death…

    Published on 4/13/2015
  • MLR-1023: Phase IIa started

    Melior Discovery Inc., Exton, Pa. Product: MLR-1023 Business: Endocrine/Metabolic Molecular target: Lyn kinase (LYN) Description: Lyn kinase (LYN) activator Indication: Treat Type II diabetes Endpoint: Change in fasting…

    Published on 4/13/2015
  • Mucogard: Phase II started

    Norgine B.V., Amsterdam, the Netherlands PlasmaTech Biopharmaceuticals Inc. (NASDAQ:PTBI), Dallas, Texas Product: Mucogard (MuGard) Business: Other Molecular target: Undisclosed Description: Mucoadhesive oral rinse …

    Published on 4/13/2015
  • Myeloid Progenitor: Phase II started

    Cellerant Therapeutics Inc., San Carlos, Calif. Product: Myeloid Progenitor (MP) Cells (CLT-008) Business: Hematology Molecular target: Not applicable Description: Cryopreserved human myeloid progenitor cells derived …

    Published on 4/13/2015
  • Nalbuphine ER: Completed Phase II/III enrollment

    Endo International plc (NASDAQ:ENDP; TSX:ENL), Dublin, Ireland Trevi Therapeutics Inc., New Haven, Conn. Product: Nalbuphine ER (T111) Business: Dermatology Molecular target: Mu opioid receptor (MOR) (OPRM1); Kappa …

    Published on 4/13/2015
  • Ornithine phenylacetate: Phase IIb amended

    Ocera Therapeutics Inc. (NASDAQ:OCRX), Palo Alto, Calif. Product: Ornithine phenylacetate (OCR-002) Business: Hepatic Molecular target: NA Description: Ammonia scavenger Indication: Treat acute hepatic encephalopathy …

    Published on 4/13/2015
  • Remimazolam: Phase III started

    Hana Pharmaceutical Co. Ltd., Seoul, South Korea Humanwell Healthcare Group Co. Ltd. (Shanghai:600079), Wuhan, China Paion AG (Xetra:PA8), Aachen, Germany PendoPharm Inc., Montreal, Quebec R-Pharm CJSC, Moscow, Russia …

    Published on 4/13/2015
  • REP 2139-Ca: Completed Phase II enrollment

    Replicor Inc., Montreal, Quebec Product: REP 2139-Ca Business: Infectious Molecular target: NA Description: Nucleic acid polymer Indication: Treat chronic HBV and HDV co-infection Endpoint: Safety; reduction in …

    Published on 4/13/2015
  • Rivipansel: Phase III start

    GlycoMimetics Inc. (NASDAQ:GLYC), Gaithersburg, Md. Pfizer Inc. (NYSE:PFE), New York, N.Y. Product: Rivipansel (GMI-1070, PF-06460031) Business: Hematology Molecular target: E selectin (SELE) (CD62E); P selectin (SELP)…

    Published on 4/13/2015
  • Telotristat etiprate: Completed Phase III enrollment

    Lexicon Pharmaceuticals Inc. (NASDAQ:LXRX), The Woodlands, Texas Product: Telotristat etiprate (LX1032, LX1606) Business: Endocrine/Metabolic Molecular target: Tryptophan hydroxylase 1 (TPH1) (TPH) Description: …

    Published on 4/13/2015
  • Topical NS2: Phase II started

    Aldeyra Therapeutics Inc. (NASDAQ:ALDX), Burlington, Mass. Product: Topical NS2 Business: Dermatology Molecular target: NA Description: Small molecule that traps and allows for the disposal of free aldehydes Indication:…

    Published on 4/13/2015
  • AKB-6548: Completed Phase II enrollment

    Akebia Therapeutics Inc. (NASDAQ:AKBA), Cambridge, Mass. Product: AKB-6548 Business: Hematology Molecular target: Hypoxia-inducible factor prolyl hydroxylase (HIF-PH) (EGLN) Description: Oral hypoxia-inducible factor …

    Published on 4/6/2015
  • AST-OPC1: Phase I/IIa started

    Asterias Biotherapeutics Inc. (NYSE-M:AST), Menlo Park, Calif. Product: AST-OPC1 Business: Neurology Molecular target: NA Description: Human embryonic stem cell (hESC)-derived oligodendrocyte progenitor cells Indication…

    Published on 4/6/2015
  • AuriPro: Phase II started

    Otonomy Inc. (NASDAQ:OTIC), San Diego, Calif. Product: AuriPro (formerly OTO-201) Business: Infectious Molecular target: DNA gyrase Description: Sustained-release gel formulation of ciprofloxacin Indication: Treat acute…

    Published on 4/6/2015
  • Aurix System: Phase IV started

    Nuo Therapeutics Inc. (OTCQX:NUOT), Gaithersburg, Md. Rohto Pharmaceutical Co. Ltd. (Tokyo:4527), Osaka, Japan Product: Aurix System, AutoloGel System Business: Dermatology Molecular target: NA Description: Device that …

    Published on 4/6/2015
  • Bardoxolone methyl: Phase II started

    Reata Pharmaceuticals Inc., Irving, Texas AbbVie Inc. (NYSE:ABBV), Chicago, Ill. Kyowa Hakko Kirin Co. Ltd. (Tokyo:4151), Tokyo, Japan Product: Bardoxolone methyl (RTA 402) Business: Renal Molecular target: Nuclear …

    Published on 4/6/2015
  • Cis-UCA Eye Drops: Completed Phase II enrollment

    Herantis Pharma plc (HSE:HRTIS), Helsinki, Finland Product: Cis-UCA Eye Drops Business: Ophthalmic Molecular target: Serotonin (5-HT2A) receptor Description: Viscous formulation of cis-urocanic acid, a serotonin (5-HT2A…

    Published on 4/6/2015

< Previous   1  2  3  4  5  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993